Kevin Weil Launches Warp Sciences With $215M in Funding

Kevin Weil, who led OpenAI's AI-for-science division until earlier this year, has emerged from stealth with Warp Sciences, a new startup focused on using artificial intelligence to automate a critical but labor-intensive phase of pharmaceutical development. The company officially launched on October 22, 2026, with $215 million in Series A funding led by Lightspeed Venture Partners, valuing the startup at $865 million post-money.

The funding round attracted participation from IVP, Premji Invest, and Lux Capital, alongside a roster of high-profile angel investors including OpenAI CFO Sarah Friar, Coinbase CEO Brian Armstrong, Palantir CTO Shyam Sankar, and LinkedIn co-founder Reid Hoffman. The strong backing reflects growing investor conviction that AI can transform traditionally manual processes in life sciences research and development.

Targeting Chemical Variant Generation

Rather than pursuing de novo drug discovery like many AI biotech startups, Warp Sciences is zeroing in on molecular optimization. After researchers identify a promising drug candidate molecule, they typically generate hundreds or thousands of chemical variants to improve efficacy and reduce side effects before human trials. This process, known as lead optimization, has historically been outsourced to contract research organizations, particularly Chinese firms like WuXi AppTec that offer faster turnaround and lower costs than Western competitors.

Weil's strategy is to reshore this work using fully automated laboratories equipped with robotic arms, AI chips, and custom machine learning models. The company's chemists will wear cameras and pressure-sensor gloves during initial experiments to capture training data for AI systems that can eventually run optimization workflows with minimal human intervention. The approach aims to match or exceed the efficiency of overseas contractors while keeping sensitive intellectual property within US borders.

Geopolitical Tailwinds and Market Timing

The startup's launch comes amid escalating US-China tensions that have disrupted pharmaceutical supply chains. In June 2026, the Pentagon designated WuXi AppTec as a firm allegedly linked to the Chinese military, prompting some clients to sever contracts. Although a federal judge blocked enforcement of that designation in August after WuXi filed suit, the episode highlighted vulnerabilities in the industry's reliance on Chinese service providers.

Pharmaceutical companies are increasingly concerned about sharing proprietary data with offshore contractors, creating an opening for domestic alternatives. Warp Sciences positions itself as both a technological and strategic solution, offering AI-powered automation that addresses both cost and security considerations. Guru Chahal, the Lightspeed partner joining Warp's board, noted that portfolio companies in the firm's life sciences practice were already asking for exactly this capability.

Team and Technical Approach

Weil is serving as CEO, joined by co-founders Manohar Paluri (former VP at Meta's Superintelligence Labs), DJ Patil (the first US Chief Data Scientist under President Obama), and Solomon Reisberg (ex-Terremoto Biosciences executive). The 20-person team has already assembled hardware infrastructure and begun generating experimental data.

The company plans to deploy a hybrid AI architecture combining frontier large language models with custom open-weight models trained on proprietary lab data. Weil emphasized that while OpenAI has achieved breakthroughs in mathematics, physical sciences remain experimentally driven domains where models need direct exposure to real-world data to deliver impact. Warp's wearable sensor approach is designed to capture that training signal at scale.

Broader AI Biotech Landscape

Warp Sciences enters a crowded but rapidly maturing market. Alphabet's Isomorphic Labs is reportedly in talks for funding at a $40 billion valuation, while OpenAI itself acquired Orchestra Bio earlier this week to incorporate AI agents into pharmaceutical workflows. The sector has attracted tens of billions in venture capital over the past two years, driven by the hypothesis that generative AI and automation can compress drug development timelines from over a decade to a handful of years.

Chahal suggested that Warp's automation platform could eventually expand beyond chemistry into other experimental disciplines, positioning the company as infrastructure for AI-accelerated science more broadly. With $215 million in the bank and a clear near-term product focus, the startup has runway to prove its thesis in a high-stakes, high-reward market.

What This Means

Kevin Weil's departure from OpenAI to found Warp Sciences underscores a broader trend of top AI researchers moving from foundation model labs into vertical applications where domain expertise and real-world data create defensible moats. By targeting a specific pharmaceutical bottleneck with automation and AI, Warp is betting it can deliver both strategic value (reshoring critical work) and economic value (matching Chinese efficiency). If successful, the model could extend to other experimentally intensive fields, accelerating the shift from software AI to embodied AI systems that operate in physical labs and manufacturing facilities.